This week, Jean-Pierre Vacher received Gérard Soula, Chairman and Adocia CEO, during an interview focused on Adocia’s challenges.
Lyon, France, September 7th, 2020 – 6:00 pm CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that CEO, Gérard Soula, will present a company overview at the H.C. Wainwright 22nd Annual
Adocia to Present Results of the 1st Phase Ib Study of M1Pram (ADO09) at the Annual Congress of the Société Francophone du Diabète (SFD) Adocia will deliver an oral presentation on the 1st Phase Ib Study of M1Pram (ADO09) (pramlintide insulin) at the Annual Congress of the Société Francophone du Diabète. The data were previously
👉 The INPI France patent list filed 2019 ranks Adocia in 4th place among French SMEs thanks to its 11 patents. Among the top 10 French SMEs, 4 are based in the Auvergne-Rhône-Alpes region. This annual ranking classifies companies by region and size. It has become a reference, highlighting the innovation effort made by the
ADA2020 Virtual Expérience is considered as a « smashing success » by organizers. More than 12,500 participants from all over the world were attending for five days scientific advances and groundbreaking research presentations on diabetes. At this occasion, Adocia was exiting to present a Poster presentation of its last results of M1Pram study programme dedicated to type
Adocia announces that an abstract relative to bi-hormonal treatment ADO09 (M1Pram) has been accepted for a poster presentation at the upcoming 80th Scientific Sessions of the American Diabetes Association® (ADA). The ADA annual meeting will take place from June 12th until 16th, 2020 as the inaugural virtual event.  . The poster presented by Adocia will
The Conference call scheduled last Monday April 27, 2020 at 6:00 pm (CET) presented Adocia results and provided a business update at the occasion of Adocia Press Release announcing positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes. Speakers: Gérard Soula, Adocia CEO Valérie Danaguezian, Financial
Adocia will hold its annual shareholders’ meeting (“AGM”) on May 28th, 2020, at 10 am at the Company’s headquarter, 115 avenue Lacassagne, 69003, Lyon, France. The notice of this shareholders’ meeting serving as convening notice is published today, in the French Bulletin des Annonces Légales Obligatoires (“BALO”), and includes the agenda, the proposed resolutions as
During the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) scheduled to take place in Madrid, Spain, 19-22 February 2020, Adocia is pleased to present the E-Poster: “ADO09, A CO-FORMULATION OF THE AMYLIN-ANALOG PRAMLINTIDE AND THE A21G HUMAN INSULIN ANALOG, LOWERS POSTPRANDIAL BLOOD GLUCOSE VERSUS INSULIN LISPRO IN TYPE 1 DIABETES